Tong Luo

Medicine · Health Sciences

14h-index890citations152works0.12yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(92), HER2/EGFR in Cancer Research(54), Glycosylation and Glycoproteins Research(25), Cancer Research and Treatments(25), Radiopharmaceutical Chemistry and Applications(24)

Publications152 total

Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Supplemental Methods 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
2025Open Access
Alpha-ketoglutarate protects against myocardial infarction via FTO-mediated anti-inflammatory macrophage activation
Basic Research in Cardiology·2025· 1 cited
Effects of antihypertensive drugs on the metabolism of mobocertinib in rats both in vitro and in vivo
Drug Metabolism and Disposition·2025
Study of a hybrid algorithm based on NSGA-II and WOA for multiobjective problems
2024
Figure S2 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors
2024Open Access
Supplemental Tables 1 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors
2024Open Access
Figure S8 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors
2024Open Access
Figure S4 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors
2024Open Access
Figure S3 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors
2024Open Access
Figure S5 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors
2024Open Access
Figure S6 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors
2024Open Access
page 1 of 8Next →

Frequent Co-authors

Neil A. O’Brien(23), Dennis J. Slamon(22), Benjamin Hoffstrom(19), KeWei Gong(19), Ming Lu(19), John A. Glaspy(19), Martina S.J. McDermott(18), Min Liang(18), Kevin Chau(18), Leonard Presta(18), Jun Zhang(17), Weiping Jia(14), Jenny J. Hong(14), Simon Davenport(14), Michael F. Press(14), Abram Handly‐Santana(14), Joan S. Brugge(14), Bin Xie(13), Richard Panayiotou(13), Ghassan S. Kassab(8)